Patrick Connor Johnson
Overview
Explore the profile of Patrick Connor Johnson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
36
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
OShea P, Johnson P, El-Jawahri A, LeBlanc T
Leuk Lymphoma
. 2025 Jan;
1-11.
PMID: 39838695
Chimeric Antigen Receptor T-Cell (CAR-T) therapy is an effective therapy and promising frontier in the treatment of hematologic malignancies. However, this revolutionary treatment has led to new challenges for patients,...
2.
Zelikson V, Gurumurthi A, Sawalha Y, Annunzio K, Saha A, Dong N, et al.
Haematologica
. 2024 Nov;
110(3):706-714.
PMID: 39540227
Outcomes in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) are poor. Loncastuximab- teserine (Lonca) is an antibody-drug conjugate which was approved by the Food and Drug Administration for...
3.
Kumar A, Soumerai J, Soumerai J, Abramson J, Barnes J, Caron P, et al.
Blood
. 2024 Oct;
145(5):497-507.
PMID: 39437708
TP53-mutant mantle cell lymphoma (MCL) is associated with poor survival outcomes with standard chemoimmunotherapy. We conducted a multicenter, phase 2 study of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in untreated patients...
4.
Johnson P, Bailey A, Ma Q, Milloy N, Biondi E, Quek R, et al.
Adv Ther
. 2024 Jul;
41(8):3342-3361.
PMID: 38976122
Introduction: Follicular lymphoma (FL) is an indolent subtype of non-Hodgkin's lymphoma (NHL), characterized by a long natural course of remissions/relapses. We aimed to evaluate real-world quality of life (QoL) in...
5.
Ababneh H, Ng A, Frigault M, Abramson J, Johnson P, Jacobson C, et al.
Haematologica
. 2023 Jun;
108(11):2972-2981.
PMID: 37317884
Despite the success of CD19-targeted chimeric antigen receptor (CAR T)-cell therapy in patients with relapsed/refractory large B-cell lymphoma (LBCL), there is a need for effective salvage strategies post-CAR T-cell therapy...
6.
Miller K, Johnson P, Abramson J, Soumerai J, Yee A, Branagan A, et al.
Blood Cancer J
. 2022 Nov;
12(10):146.
PMID: 36316312
Chimeric antigen receptor T cells (CAR T) are groundbreaking therapies but may cause significant toxicities including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and cytopenias. Granulocyte colony-stimulating...
7.
Amonoo H, Bodd M, Reynolds M, Nelson A, Newcomb R, Johnson P, et al.
Blood Adv
. 2021 Nov;
6(7):2435-2442.
PMID: 34768282
Patients diagnosed with acute myeloid leukemia (AML) face sudden-onset life-threatening disease that requires intensive treatments. Although their early disease trajectory is characterized by significant, toxic side effects, limited data are...
8.
How J, Johnson P, Corrales C, Wright K, Justicz N, Chen J, et al.
Am J Hematol
. 2019 Mar;
94(6):728-732.
PMID: 30916796
No abstract available.